Financial Summary (All financials)
| In millions of CNY, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 123,675.0 | 124,493.0 | 107,074.0 | 107,413.0 | 102,277.0 | 84,809.0 | 70,549.0 | 66,382.0 |
| Revenue growth | -0.7% | 16.3% | -0.3% | 5.0% | 20.6% | 20.2% | 6.3% | 35.3% |
| Cost of goods sold | 63,935.0 | 64,314.0 | 55,158.0 | 62,850.0 | 51,744.0 | 43,062.0 | 35,278.0 | 27,458.0 |
| Gross profit | 59,740.0 | 60,179.0 | 51,916.0 | 44,563.0 | 50,533.0 | 41,747.0 | 35,271.0 | 38,924.0 |
| Gross margin | 48.3% | 48.3% | 48.5% | 41.5% | 49.4% | 49.2% | 50.0% | 58.6% |
| Selling, general and administrative | 20,514.0 | 24,723.0 | 18,063.0 | 19,910.0 | 19,231.0 | 13,128.0 | 15,071.0 | 17,076.0 |
| Research and development | 23,315.0 | 24,938.0 | 19,513.0 | 18,346.0 | 15,772.0 | 12,928.0 | 10,151.0 | 10,176.0 |
| EBITA | 14,468.0 | 10,057.0 | 12,636.0 | 5,714.0 | 15,836.0 | 23,571.0 | 13,899.0 | 14,176.0 |
| EBITA margin | 11.7% | 8.1% | 11.8% | 5.3% | 15.5% | 27.8% | 19.7% | 21.4% |
| Amortization of intangibles | 467.0 | 471.0 | 544.0 | 661.0 | 385.0 | 7,943.0 | 4,876.0 | 2,500.0 |
| EBIT | 14,001.0 | 9,586.0 | 12,092.0 | 5,053.0 | 15,451.0 | 15,628.0 | 9,023.0 | 11,676.0 |
| EBIT margin | 11.3% | 7.7% | 11.3% | 4.7% | 15.1% | 18.4% | 12.8% | 17.6% |
| Pre-tax income | 10,112.0 | 10,778.0 | 23,090.0 | -340.0 | 27,325.0 | 21,283.0 | 14,509.0 | 37,907.0 |
| Income taxes | 2,578.0 | 3,187.0 | 4,064.0 | 1,948.0 | 4,743.0 | 2,995.0 | 2,913.0 | 5,475.0 |
| Tax rate | 25.5% | 29.6% | 17.6% | | 17.4% | 14.1% | 20.1% | 14.4% |
| Net income | 7,559.0 | 10,226.0 | 22,472.0 | 2,057.0 | 27,573.0 | 18,301.0 | 11,632.0 | 33,664.0 |
| Net margin | 6.1% | 8.2% | 21.0% | 1.9% | 27.0% | 21.6% | 16.5% | 50.7% |
| |
| Diluted EPS | $1.23 | $1.65 | $3.69 | $0.33 | $4.44 | $237.17 | $151.23 | $434.03 |
| Shares outstanding (diluted) | 6,168.0 | 6,188.0 | 6,086.0 | 6,158.0 | 6,204.0 | 77.2 | 76.9 | 77.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|